FindTrial
Sign In

Effectiveness and Safety of Belumosudil for Chronic Graft versus Host Disease (cGVHD) Treatment in Chinese Patients: a Multicenter Observational Study

Effectiveness and Safety of Belumosudil for Chronic Graft versus Host Disease (cGVHD) Treatment in Chinese Patients: a Multicenter Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114026
Enrollment
Unknown
Registered
2025-12-05
Start date
2025-12-30
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Graft versus Host Disease (cGVHD)

Interventions

Case group:NA

Sponsors

Peking University People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male and female patients; 2. Age 12 years or older at index date (belumosudil initiation); 3. A record of alloHCT; 4. cGVHD diagnosis and treated at study sites; 5. Initiated belumosudil as >= 2L cGVHD treatment, prescribed in real-world clinical practice, with start date of belumosudil at least 6 months prior to enrolment; 6. Written informed consent or a waiver by the Ethics Committee (EC) at the sites.

Exclusion criteria

Exclusion criteria: Patients who are currently enrolled in clinical trials at index date.

Design outcomes

Primary

MeasureTime frame
ORR by 6 months;—

Secondary

MeasureTime frame
ORR by 6 months by each of the subgroups;Response by organ system;DoR;Time to response (TTR);Time to next treatment (TTNT);Change in corticosteroid dose;Change in calcineurin inhibitor dose;—

Countries

China

Contacts

Public ContactXiaojun Huang

Peking University People’s Hospital

huangxiaojun@bjmu.edu.cn+86 10 8832 4577

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026